In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led to hospitalization and a diagnosis of ...
Zacks Investment Research on MSN
KROS stock: What to know about Rinvatercept in DMD
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular ...
6don MSNOpinion
Trump's FDA is breaking promises to kids like mine | Opinion
Kids with Duchenne muscular dystrophy and their families deserve the chance to decide their own future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results